S&P 500 falls even with most stocks rising as traders dump AI names
The S&P 500 fell 0.6% despite having far more gainers than losers.
The nascent pullback across high-flying, AI-linked names picked up steam on Tuesday, sending major indexes down even as most stocks went up.
The S&P 500 fell 0.6% despite having far more gainers than losers, the Nasdaq 100 tumbled 1.4%, and the Russell 2000 gave back 0.8%.
The iShares MSCI USA Momentum Factor ETF had its worst day since the opening session of Q3, with Palantir leading S&P decliners. The AI darling fell 9.3% to match its longest losing streak since April 2024.
As you’d expect given the tape, with indexes down despite most stocks rising, the pain at the S&P 500 sector ETF level was concentrated in tech — communication services and consumer discretionary were the only other two sectors to fall on Tuesday. Morgan Stanley’s basket of AI tech beneficiaries suffered its biggest one-day drop since April 10, falling 4.1%.
Gains on the day were led by Intel, which rose 6.9% after the company reported that Japanese tech giant SoftBank Group was buying a $2 billion stake in the US chipmaker. Elsewhere...
Home Depot shares were up 3.2% after the home improvement retailer turned in weaker-than-expected Q2 results but doubled down on its full-year outlook.
Best Buy shares were up 3.3% after the electronics retailer announced plans to launch a new third-party marketplace, expanding its online assortment beyond tech.
Palo Alto Networks was a rare sight on Tuesday: an AI-linked name that performed well. Shares jumped 3% after posting top- and bottom-line beats in the fourth quarter along with a bright outlook for its current fiscal year.
Meta shares were down about 2% as the tech giant announced internally that it’s splitting its AI division. The decisions reportedly include moving employees, AI executive exits, and eliminating some roles.
Fabrinet shares sank 12.8% after the maker of optical communication devices said that sales in its data communication business are expected to fall in the current quarter.
Viking Therapeutics fell 42% after the company reported trial results for its weight-loss pill Tuesday morning that disappointed investors.